NASDAQ:SRZN Surrozen (SRZN) Stock Price, News & Analysis $33.68 +17.52 (+108.42%) Closing price 04:00 PM EasternExtended Trading$34.04 +0.36 (+1.07%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Surrozen Stock (NASDAQ:SRZN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Surrozen alerts:Sign Up Key Stats Today's Range$29.10▼$35.8650-Day Range$16.16▼$25.6252-Week Range$11.39▼$35.86Volume11.45 million shsAverage Volume209,900 shsMarket Capitalization$391.02 millionP/E RatioN/ADividend YieldN/APrice Target$45.00Consensus RatingModerate Buy Company Overview Surrozen, Inc. is a clinical-stage biotechnology company developing regenerative medicines designed to activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen’s approach is intended to stimulate the pathway selectively in specific tissues while limiting unwanted effects elsewhere in the body. The company’s product candidates are based on engineered antibody therapeutics and its proprietary SWEETS platform. Surrozen has focused its research on potential treatments for diseases affecting the liver, gastrointestinal system and eyes, where impaired tissue repair or abnormal signaling may contribute to disease progression. Its pipeline has included candidates such as SZN-043, SZN-1326 and SZN-413, which have been studied or developed for selected inflammatory, fibrotic and regenerative indications. Surrozen was founded to translate advances in Wnt biology into medicines and became a publicly traded company on the Nasdaq under the symbol SRZN. As a development-stage biotechnology company, it has concentrated primarily on research, clinical development and partnerships rather than commercial product sales. The company’s programs remain subject to clinical, regulatory and funding risks typical of the biotechnology industry.AI Generated. May Contain Errors. Read More Surrozen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreSRZN MarketRank™: Surrozen scored higher than 59% of companies evaluated by MarketBeat, and ranked 467th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingSurrozen has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSurrozen has a consensus price target of $45.00, representing about 33.4% upside from its current price of $33.73.Amount of Analyst CoverageSurrozen has only been the subject of 4 research reports in the past 90 days.Read more about Surrozen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Surrozen is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surrozen is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Surrozen's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.24% of the float of Surrozen has been sold short.Short Interest Ratio / Days to CoverSurrozen has a short interest ratio ("days to cover") of 7.73.Change versus previous monthShort interest in Surrozen has recently increased by 15.35%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSurrozen does not currently pay a dividend.Dividend GrowthSurrozen does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.67 News SentimentSurrozen has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Surrozen this week, compared to 3 articles on an average week.Search Interest2 people have searched for SRZN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Surrozen to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Surrozen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,906,250.00 in company stock.Percentage Held by Insiders31.74% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Surrozen's insider trading history. Receive SRZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRZN Stock News HeadlinesSurrozen, Inc. (NASDAQ:SRZN) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 23 at 4:59 AM | americanbankingnews.comSurrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Surrozen (SRZN), Liquidia Technologies (LQDA) and Universal Health (UHS)September 11, 2026 | theglobeandmail.comSurrozen Submits IND Application For SZN-8141 In Diabetic Macular EdemaSeptember 8, 2026 | rttnews.comSurrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaSeptember 8, 2026 | globenewswire.comSurrozen to Present at Upcoming Healthcare Investor ConferencesSeptember 2, 2026 | globenewswire.comSurrozen Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 6, 2026 | globenewswire.comSee More Headlines SRZN Stock Analysis - Frequently Asked Questions How have SRZN shares performed this year? Surrozen's stock was trading at $22.60 on January 1st, 2026. Since then, SRZN stock has increased by 49.2% and is now trading at $33.7260. How were Surrozen's earnings last quarter? Surrozen, Inc. (NASDAQ:SRZN) announced its earnings results on Thursday, August, 6th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.88. The business earned $5 million during the quarter, compared to analysts' expectations of $0.47 million. When did Surrozen's stock split? Surrozen shares reverse split on the morning of Thursday, December 14th 2023.The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Surrozen's major shareholders? Surrozen's top institutional investors include Braidwell LP (3.37%), 5AM Venture Management LLC (2.34%), Bank of New York Mellon Corp (0.13%) and California State Teachers Retirement System. Insiders that own company stock include Group Gp Lp Column III, Tim Kutzkey, Tcg Crossover Gp Ii, Llc, Yang Li, Charles O Williams and Craig C Parker. View institutional ownership trends. How do I buy shares of Surrozen? Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Surrozen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Surrozen investors own include ACADIA Pharmaceuticals (ACAD), Marvell Technology (MRVL), HubSpot (HUBS), Avidity Biosciences (RNA), Adverum Biotechnologies (ADVM), Alpha and Omega Semiconductor (AOSL) and Company Calendar Last Earnings8/06/2026Today9/24/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, SRZN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SRZN CIK1824893 Webwww.surrozen.com Phone650-489-9000FaxN/AEmployees44Year Founded2016Price Target and Rating Average Price Target for Surrozen$45.00 High Price Target$51.00 Low Price Target$40.00 Potential Upside/Downside+33.6%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($40.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$242.03 million Net Margins-2,885.33% Pretax Margin-2,885.33% Return on EquityN/A Return on Assets-93.62% Debt Debt-to-Equity RatioN/A Current Ratio12.14 Quick Ratio12.14 Sales & Book Value Annual Sales$11.51 million Price / Sales33.97 Cash FlowN/A Price / Cash FlowN/A Book Value($19.21) per share Price / Book-1.75Miscellaneous Outstanding Shares11,610,000Free Float7,925,000Market Cap$391.02 million OptionableNot Optionable Beta0.56 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SRZN) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
